Rating Change
Barclays reiterated its Overweight rating on IDEXX Laboratories, Inc. (NASDAQ:IDXX) on August 11, 2026.
reiterateNASDAQ:IDXX
Barclays Reiterates Overweight Rating on IDEXX Laboratories, Inc. (IDXX)
Barclays reiterated its Overweight rating on IDEXX Laboratories, Inc. (NASDAQ:IDXX) on August 11, 2026.
At publication ·
What changed
IDEXX Laboratories, Inc. (NASDAQ:IDXX) · reiterate
- Firm
- Barclays
- Rating
- Overweight to Overweight
- Price at event
- $590.45
- Market capitalization
- $56.5B
At a glance
Key takeaways
- Barclays reiterated an Overweight rating on IDEXX Laboratories on August 11, 2026, while the stock trades at $590.45 with a market capitalization of $56.5 billion.
Market Context
IDEXX Laboratories, Inc. operates in the Healthcare sector. The stock currently trades at $590.45 with a market capitalization of $56.5B. The stock has declined 17.9% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for IDEXX Laboratories, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for IDEXX Laboratories, Inc.
Among the 10 most recent ratings: 3 Buy, 7 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 11, 2026 | Barclays | Overweight | N/A |
| Aug 05, 2026 | UBS | Neutral | N/A |
| Aug 05, 2026 | Citigroup | Neutral | N/A |
| Jul 27, 2026 | UBS | Neutral | N/A |
| Apr 28, 2026 | UBS | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View IDXX Stock Page
Frequently Asked Questions
What does the Overweight rating mean for IDXX?
A rating of Overweight from Barclays reflects the analyst's outlook on IDEXX Laboratories, Inc. (NASDAQ:IDXX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the IDXX forecast page.
